For individuals with migraine frequency of 4 to 14 episodes per month, prophylactic medications and analgesics are required.
Allergan has reported positive results from the first of 2 Phase 3 trials for ubrogepant for the treatment of migraine.
The FDA has granted GammaCore 510(k) expanded clearance to treat migraine related pain.
Amgen announced that erenumab met its primary endpoint in reducing monthly migraine days.
Prior physical or sexual abuse of survivors increased the likelihood of migraine or tension-type headache.
The PSEQ successfully shows the debility in migraine surgery patients, and puts migraine pain to perspective.
Patients were randomly assigned to receive eptinezumab (300mg or 100mg) or placebo once every 12 weeks.
For patients with chronic migraine, onabotulinumtoxinA was shown to have a better outcome.
In a case report, a 21 year old female's migraine was successfully treated with therapy specifically aimed at the herpes simplex virus.
Researchers report that a behavioral weight loss program may be effective in reducing migraine headaches as social support from a group of people facing similar circumstances may help patients cope.
Women with migraine should avoid high-risk products such as combined oral HCs consisting of >35μg ethinylestradiol.
Neurology Advisor Articles
- FDA Approves Blood Test to Assess Concussion
- Erenumab for Episodic Migraine: A Closer Look at the Data
- Shortcomings in ALS Research: Strategies for Improvement
- Factors Predictive of Mild Cognitive Impairment in Healthy Individuals
- Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- Plasma Neurofilament Light Indicative of Neuronal Damage in Huntington Disease
- New Glatiramer Acetate Dose Available for Relapsing Multiple Sclerosis
- Clinicians Should Not Refuse Treatment Based on Personal Beliefs
- Prevalence of Fetal Alcohol Syndrome in the US